Seres Therapeutics Inc earnings missed by $0.06, revenue fell short of estimates

Investing.com - Seres Therapeutics Inc (NASDAQ: MCRB) reported first quarter EPS of $-0.51, $0.06 worse than the analyst estimate of $-0.46. Revenue for the quarter came in at $974K versus the consensus estimate of $6M.
Seres Therapeutics Inc's stock price closed at $5.49. It is down -15.93% in the last 3 months and down -18.79% in the last 12 months.
Seres Therapeutics Inc saw 4 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Seres Therapeutics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, Seres Therapeutics Inc's Financial Health score is "weak performance".
Check out Seres Therapeutics Inc's recent earnings performance , and Seres Therapeutics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or